- Conditions
- Symptomatic Functional MR 3 or Greater
- Interventions
- This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.
- Device
- Lead sponsor
- Valcare Medical Ltd.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • La Jolla, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 21, 2026, 11:38 PM EDT